Go to the content. | Move to the navigation | Go to the site search | Go to the menu | Contacts | Accessibility

| Create Account

Senter, Riccardo (2018) I linfociti TREG e TH17 nei pazienti con orticaria cronica spontanea. [Ph.D. thesis]

Full text disponibile come:

[img]
Preview
PDF Document
786Kb

Abstract (english)

Background: the skin reactivity against Autologous Serum (SA) and the presence of anti-IgE and anti-IgE receptor, which are found in some patients with Chronic Spontaneous Urticaria (CSU), have suggested that this disease could have an autoimmune pathogenesis, although the actual causative mechanism is still unknown. It is well recognized, however, that mast cells play a key role in the pathogenesis, and recent studies show that they likely have a role in directing lymphocyte differentiation towards TH1 and TH17 subsets.

Aim: to assess Treg and TH17 levels between CSU patients and healthy controls in different disease severity and different skin reactivity against SA.

Methods: surface and intracellular antigens expression has been evaluated in peripheral blood mononuclear cells (PBMC) of CSU patients and healthy controls through flow cytometry, using monoclonal antibodies. Cells expressing CD4, CD25 and FOXP3 were considered Treg, while cells expressing CD4 and IL23R or IL17 or both were considered TH17.

Results: no significant differences have been found between CSU patients and healthy controls regarding Treg levels, FOXP3 expression on Treg and ratio Treg/TH17. Furthermore, no significant differences have been found between the two groups regarding levels of IL23R+CD4+, IL23R+CD4+IL17+ and IL17+CD4+ cells. However, a remarkable increase of IL17+CD4+ cells level has been found in CSU patients comparing with healthy controls, with significant correlation between IL17+CD4+ cells levels and disease activity, estimated by the Urticaria Activity Score (UAS).

Conclusions: IL17+CD4+ cells level is correlated with disease activity in CSU patients, thus suggesting a role of IL17+CD4+ cells in the pathogenesis of the disease.

Abstract (italian)

Introduzione: la reattività cutanea nei riguardi del siero autologo (SA) e la presenza di anticorpi anti - IgE ed anti -recettore per le IgE che caratterizzano alcuni pazienti con orticaria cronica spontanea (CSU) hanno suggerito una patogenesi autoimmunitaria della malattia, ma l’effettivo meccanismo causale resta oscuro. E’ comunque noto che i mastociti rivestono un ruolo fondamentale nella patogenesi , e recenti lavori suggeriscono un loro probabile ruolo di polarizzazione dei linfociti T helper in senso TH1 e TH17.

Scopo dello studio: valutare l’andamento di Treg e TH17 nei pazienti con CSU rispetto a controlli sani nelle diverse fasi cliniche e in relazione alla reattività cutanea nei confronti del siero autologo.

Metodi: l’espressione degli antigeni di superficie e intracitoplasmatici di Treg e TH17 sulle cellule mononucleate del sangue periferico (PBMC) dei pazienti con CSU e dei controlli è stata valutata mediante citometria a flusso. Per identificare i Treg sono stati utilizzati anticorpi monoclonali (AcM) rivolti verso CD4, CD25 e il fattore di trascrizione Forkhead box P3 (FOXP3), mentre per identificare i TH17 sono stati utilizzati AcM rivolti verso CD4, il recettore per l’Interleuchina 23 (IL23R) e l’Interleuchina 17 (IL17).

Risultati: non sono emerse differenze significative tra i due gruppi per quanto riguarda il numero di linfociti Treg circolanti, la loro espressione di FOXP3 e il rapporto Treg/TH17. Per quanto riguarda i TH17 non sono emerse differenze significative nei gruppi cellulari analizzati (IL23R+CD4+, IL23R+CD4+IL17+, IL17+CD4+), ma abbiamo osservato un rilevante aumento della percentuale di cellule IL17+CD4+ nei pazienti affetti da CSU rispetto ai controlli, con una significativa correlazione tra % di cellule IL17+CD4+ e grado di severità di malattia calcolata con l’Urticaria Activity Score (UAS).

Conclusioni : L’aumento di cellule IL17+CD4+ correla con il grado di attività di malattia e suggerisce un coinvolgimento dei TH17 nella patogenesi della CSU.

Statistiche Download
EPrint type:Ph.D. thesis
Tutor:Giannini, Sandro
Ph.D. course:Ciclo 30 > Corsi 30 > SCIENZE CLINICHE E SPERIMENTALI
Data di deposito della tesi:14 January 2018
Anno di Pubblicazione:14 January 2018
Key Words:Orticaria Cronica Spontanea Chronic Spontaneous Urticaria Thelper17 Treg
Settori scientifico-disciplinari MIUR:Area 06 - Scienze mediche > MED/09 Medicina interna
Struttura di riferimento:Dipartimenti > Dipartimento di Medicina
Codice ID:10793
Depositato il:25 Oct 2018 17:00
Simple Metadata
Full Metadata
EndNote Format

Bibliografia

I riferimenti della bibliografia possono essere cercati con Cerca la citazione di AIRE, copiando il titolo dell'articolo (o del libro) e la rivista (se presente) nei campi appositi di "Cerca la Citazione di AIRE".
Le url contenute in alcuni riferimenti sono raggiungibili cliccando sul link alla fine della citazione (Vai!) e tramite Google (Ricerca con Google). Il risultato dipende dalla formattazione della citazione.

1. Maurer M, Weller K, Bindslev-Jensen C, Gimenez-Arnau A, Bousquet PJ, Bousquet J, Canonica GW, Church MK, Godse KV, Grattan CEH, Greaves MW, Hide M, Kalogeromitros D, Kaplan AP, Saini SS, Zhu XJ, Zuberbier T: Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy 2011; 66: 317–330. Cerca con Google

2. Cancian M, Bortolati M, Fagiolo U: Urticaria e angioedema. Ann Ital Med Int 2003; 18: 16-23 Cerca con Google

3. Powell RJ, Du Toit GL, Siddique N, Leech SC, Dixon TA, Clark AT, Mirakian R, Walker SM, Huber PA, Nasser SM, British SCSUety for Allergy and Clinical Immunology (BSACI): BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy 2007; 37: 631-50 Cerca con Google

4. Grattan CE, Humphreys F, British Association of Dermatologists Therapy Guidelines and Audit Subcommittee: Guidelines for evaluation and management of urticaria in adults andchildren. Br J Dermatol 2007; 157: 1116-23 Cerca con Google

5. Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, Church MK, Ensina LF, Giménez-Arnau A, Godse K, Gonçalo M, Grattan C, Hebert J, Hide M, Kaplan A, Kapp A, Abdul Latiff AH, Mathelier-Fusade P, Metz M, Nast A, Saini SS, Sánchez-Borges M, Schmid-Grendelmeier P, Simons FE, Staubach P, Sussman G, Toubi E, Vena GA, Wedi B, Zhu XJ, Maurer M; European Academy of Allergy and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum: World Allergy Organization: The EAACI/GA(2)LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014 Jul;69(7):868-87 Cerca con Google

6. Supramaniam G, Warner JO: Artificial food additive intolerance in patients with angio-oedema and urticaria. Lancet 1986; 8512: 907-9 Cerca con Google

7. Zuberbier T, Czarnetzki BM: High response to additive-free diet in chronic urticaria. Br J Dermatol 1996; 134: 1159 Cerca con Google

8. Ehlers I, Niggermann B, Binder C, Zuberbier T: Role of nonallergic hypersensitivity reactions in children with chronic urticaria. Allergy 1998; 53: 1074-7 Cerca con Google

9. Gibson A, Claucy R: Management of chronic urticaria by the identification and the exclusion of dietary factors. Clin Allergy 1998; 10: 699-704 Cerca con Google

10. Settipane RA, Constantine HP, Settipane GA: Aspirin intolerance and recurrent urticaria in normal adults and children. Allergy 1980; 35: 149-54 Cerca con Google

11. Grattan CEH: Aspirin sensitivity and urticaria. Clin Exp Dermatol 2003; 28: 123-7 Cerca con Google

12. Asero R: Intolerance to nonsteroidal anti-inflammatory drugs may precede by years the onset of chronic urticaria. J Allergy Clin Immunol 2003; 111: 1095-8 Cerca con Google

13. Stevenson DD: Aspirin and NSAID sensitivity. Immunol Allergy Clin N Am 2004; 24: 491-505 Cerca con Google

14. Warin RP: The effect of aspirin in chronic urticaria. Br J Dermatol 1960; 72: 350-1 Cerca con Google

15. Grzelewska-Rzymowska M, Szmidt M, Rozniecki J: Urticaria/angioedema type sensitivity to aspirin and other non steroidal anti-inflammatory drugs: diagnostic value of anamnesis and challenge test with acetylsalicylic acid. J Invest Allergol Clin Immunol 1992; 2: 191-5 Cerca con Google

16. Kaplan AP, Greaves M: Pathogenesis of chronic urticaria. Clin Exp Allergy 2009; 39: 777-87 Cerca con Google

17. O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW: The impact of chronic urticaria on the quality of life. Br J Dermatol 1997; 136: 197-201 Cerca con Google

18. Pasaoglu G, Bavbek S, Tugcu H, Abadoglu O, Misirligil Z: Psychological status of patients with chronic urticaria. J Dermatol. 2006; 33: 765-71 Cerca con Google

19. Ozkan M, Oflaz SB, Kocaman N, Ozseker F, Gelincik A, Büyüköztürk S, Ozkan S, Colakoğlu B: Psychiatric morbidity and quality of life in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2007; 99: 29-33 Cerca con Google

20. Leznoff A, Josse RG, Denburg J, Dolovich J: Association of chronic urticaria and angioedema with thyroid autoimmunity. Arch Dermatol 1983; 119: 636-40 Cerca con Google

21. Leznoff A, Sussman GL: Syndrome of idiopathic chronic urticaria and angioedema with thyroid autoimmunity: a study of 90 patients. J Allergy Clin Immunol 1989; 84: 66-71 Cerca con Google

22. Turktas I, Gokcora N, Demirsoy S, Cakir N, Onal E: The association of chronic urticarial and angioedema with autoimmune thyroiditis. Int J Dermatol 1997; 36:187-90 Cerca con Google

23. Toubi E, Kessel A, Avshovich N, Bamberger E, Sabo E, Nusem D, Panasoff J: Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients. Allergy 2004; 59: 869-73 Cerca con Google

24. Verneuil L, Leconte C, Ballet JJ, Coffin C, Laroche D, Izard JP, Reznik Y, Leroy D: Association between chronic urticaria and thyroid autoimmunity: a prospective study involving 99 patients. Dermatology 2004; 208: 98-103 Cerca con Google

25. Doutre MS: Chronic urticaria and thyroid auto-immunity. Clin Rev Allergy Immunol 2006; 30: 31-7 Cerca con Google

26. Tharp MD: Chronic urticaria: pathophysiology and treatment approaches. J Allergy Clin Immunol 1996; 98: S325-30 Cerca con Google

27. Elias J, Boss E, Kaplan A: Studies of the cellular infiltrate of chronic idiopathic urticaria: prominence of T-lymphocytes, monocytes, and mast cells. J Allergy Clin Immunol 1986; 78: 914–8 Cerca con Google

28. Nettis E, Dambra P, Loria MP, Cenci L, Vena GA, Ferrannini A, Tursi A: Mast-cell phenotype in urticaria. Allergy 2001; 56: 915–9 Cerca con Google

29. Smith CH, Kepley C, Schwartz LB, Lee TH: Mast cell number and phenotype in chronic idiopathic urticaria. J Allergy Clin Immunol 1995; 96: 360-4 Cerca con Google

30. Natbony S, Phillips M, Elias J, Godfrey H, Kaplan A: Histologic studies of chronic idiopathic urticaria. J Allergy Clin Immunol 1983; 71: 177–83 Cerca con Google

31. Haas N, Toppe E, Henz B. Microscopic morphology of different types of urticaria. Arch Dermatol 1998; 134: 41–6 Cerca con Google

32. Sabroe R, Poon E, Orchard GE Lane D, Francis DM, Barr RM, Black MM, Black AK, Greaves MW: Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: comparison of patients with and without anti-FcepsilonRI or anti-IgE autoantibodies. J Allergy Clin Immunol 1999; 103: 484–93 Cerca con Google

33. Peters M, Schroeter A, Kephart G, Gleich G: Localization of eosinophil granule major basic protein in chronic urticaria. J Invest Dermatol 1983; 81: 39–43 Cerca con Google

34. Ying S, Robinson DS, Meng Q Barata LT, McEuen AR, Buckley MG, Walls AF, Askenase PW, Kay AB: C-C chemokines in allergen induced late-phase cutaneous responses in atopic subjects: association of eotaxin with early 6-hour eosinophils, and of eotaxin-2 and monocyte chemoattractant protein-4 with the later 24-hour tissue eosinophilia, and relationship to basophils and other C-C chemokines (monocyte chemoattractant protein-3 and RANTES). J Immunol 1999; 163: 3976–84 Cerca con Google

35. Grattan CE, Wallington TB, Warin RP, Kennedy CT, Bradfield JW: A serological mediator in chronic idiopathic urticaria--a clinical, immunological and histological evaluation. Br J Dermatol 1986; 114: 583-90 Cerca con Google

36. Grattan CE, Francis DM, Hide M, Greaves MW : Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. Clin Exp Allergy 1991; 21: 695-704 Cerca con Google

37. Niimi N, Francis DM, Kermani F, O'Donnell BF, Hide M, Kobza-Black A, Winkelmann RK, Greaves MW, Barr RM: Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. J Invest Dermatol 1996; 106: 1001-6 Cerca con Google

38. Fagiolo U, Cancian M, Bertollo L, Peserico A, Amadori A: Inhibitory effect of heparin on skin reactivity to autologous serum in chronic idiopathic urticaria. J Allergy Clin Immunol 1999; 103: 1143-7 Cerca con Google

39. Sabroe RA, Grattan CEH, Francis DM, Barr RM, Kobza Black A, Greaves MW: The autologous serum skin test: a screening for autoantibodies in chronic idiopathic urticaria. BrJ Dermatol 1999; 140: 446-52 Cerca con Google

40. Greaves MW: Pathophysiology of chronic urticaria. Int Arch Allergy Immunol 2002;127:3-9 Cerca con Google

41. Grattan CEH: Autoimmune urticaria. Immunol Allergy Clin N Am 2004; 24: 163-81 Cerca con Google

42. Kozel MMA, Sabroe RA: Chronic urticaria. Drugs 2004; 64: 2515-36 Cerca con Google

43. Kaplan AP: Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 2004; 114: 465-7 Cerca con Google

44. Gruber BL, Baeza ML, Marchese MJ, Agnello V, Kaplan AP: Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. J Invest Dermatol 1988; 90: 213-7 Cerca con Google

45. Fagiolo U, Quinti I, Ossi E, Scala E, Cancian M, Carmini D, Paganelli R: Auto-anti-IgE antibodies and immunocomplexes in chronic urticaria-angioedema syndrome with and without joint symptoms. Ital J Allergy Clin Immunol 1991; 1: 147-51 Cerca con Google

46. Hide M, Francis DM, Grattan CE, Hakimi J, Kochan JP, Greaves MW: Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993; 328: 1599-604 Cerca con Google

47. Fiebiger E, Maurer D, Holub H, Reininger B, Hartmann G, Woisetschläger M, Kinet JP, Stingl G: Serum IgG autoantibodies directed against the alpha chain of Fc epsilon RI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients? J Clin Invest 1995; 96: 2606-12 Cerca con Google

48. Bieber T: FcRI on antigen presenting cells. Curr Opin Immunol 1996; 8: 773-7 Cerca con Google

49. Kinet JP: The high affinity IgE receptor (FcRI): from physiology to pathology. Annu Rev Immunol 1999; 17: 931-72 Cerca con Google

50. Fiebiger E, Hammerschmid F, Stingl G, Maurer D: Anti-FcRIautoantibodies in autoimmune-mediated disorders. J Clin Invest 1998; 101: 243-51 Cerca con Google

51. Ferrer M, Kinét JP, Kaplan AP: Comparative studies of functional and binding assays for IgG anti-Fc(epsilon)RIalpha (alpha-subunit) in chronic urticaria. J Allergy Clin Immunol 1998; 101: 672-6 Cerca con Google

52. Ferrer M, Nakazawa K, Kaplan AP: Complement dependence of histamine release in chronic urticaria. J Allergy Clin Immunol 1999; 104: 169-72 Cerca con Google

53. Zuberbier T, Henz BM, Fiebiger E, Maurer D, Stingl G: Anti-FcRIserum antibodies in different subtypes of urticaria. Allergy 2000; 55: 951-4 Cerca con Google

54. Ferrer M, Luquin E, Sanchez-Ibarrola A, Moreno C, Sanz ML, Kaplan AP: Secretion of cytokines, histamine and leukotrienes in chronic urticaria. Int Arch Allergy Clin Immunol 2002; 129: 254-60 Cerca con Google

55. Kikuchi Y, Kaplan AP: A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria. J Allergy Clin Immunol 2002; 109: 114-8 Cerca con Google

56. Asero R, Lorini M, Chong SU, Zuberbier T, Tedeschi A: Assessment of histamine-releasing activity of sera from patients with chronic urticaria showing positive autologous skin test on human basophils and mast cells. Clin Exp Allergy 2004; 34: 1111-14 Cerca con Google

57. Grattan CEH, Dawn G, Gibbs S, Francis DM: Blood basophil number in chronic ordinary urticaria and healthy controls: diurnal variation, influence of loratadine and prednisolone and relationship to disease activity. Clin Exp Allergy 2003; 33: 337-41 Cerca con Google

58. Lapolla W et al: Clinical utility of testing for autoimmunity in chronic idiopathic urticaria. J Am Acad Dermatol 2012; volume 66, number 3. Cerca con Google

59. Cancian M, Bendo R, Bertollo L, Tomsic M, Paganelli R, Peserico A, Fagiolo U: Clinical, biochemical and immunologic findings in chronic urticaria with skin reactivity to autologous serum. Ital J Allergol Immunol 1998; 8: 518-22 Cerca con Google

60. O'Donnell BF, O'Neill CM, Francis DM, Niimi N, Barr RM, Barlow RJ, Kobza Black A, Welsh KI, Greaves MW: Human leucocyte antigen class II associations in chronic idiopathic urticaria. Br J Dermatol 1999; 140: 853-8 Cerca con Google

61. O’Donnell BF, Barr RM, Kobza Black A, Francis DM, Kermani F, Niimi N, Barlow RJ, Winkelmann RK, Greaves MW: Intravenous immunoglobulin in autoimmune chronic urticaria. Br J Dermatol 1998; 138: 101-6 Cerca con Google

62. Kroiss M, Vogt T, Landthaler M, Stolz W: The effectiveness of low-dose intravenous immunoglobulin in chronic urticaria. Acta Derm Venereol 2000; 80: 225 Cerca con Google

63. Grattan CEH, Francis DM, Slater NGP, Barlow RJ, Greaves MW: Plasmapheresis for severe unremitting chronic urticaria. Lancet 1992; 339: 1078-80 Cerca con Google

64. Barlow RJ, Kobza Black A, Greaves MW: Treatment of severe, chronic urticaria with cyclosporin A. Eur J Dermatol 1993; 3: 273-5 Cerca con Google

65. Toubi E, Blant A, Kessel A, Golan TD: Low-dose cyclosporin A in the treatment of severe chronic idiopathic urticaria. Allergy 1997; 52: 312-16 Cerca con Google

66. Grattan CEH, O’Donnel BF, Francis DM, Niimi N, Barlow RJ, Seed PT, Kobza Black A, Greaves MW: Randomized double-blind study of cyclosporin in chronic idiopathic urticaria. Br J Dermatol 2000; 143: 365-72 Cerca con Google

67. Bernstein JA, Garriamone SM, Lower GE: Successful treatment of autoimmune chronic idiopathic urticaria with intravenous cyclophosphamide. Ann Allergy Asthma Immunol 2002; 89: 212-14 Cerca con Google

68. Puech-Plottova I, Michel J, Rouchouse B, Perrot J, Dzviga C, Cambazard F: Solar urticaria: one case treated by intravenous immunoglobulin. Ann Dermatol Venereol 2000; 127: 831-5 Cerca con Google

69. Sahu A, Pangburn MK: Identification of multiple sites of interaction between heparin and the complement system. Mol Immunol 1993; 30: 679-84 Cerca con Google

70. Kalpaklioglu AF, Demirel YS, Saryal S, Misirligil Z: Effect of pretreatment with heparin on pulmonary and cutaneous response. J Asthma 1997; 34: 337-43 Cerca con Google

71. Tyrrell DJ, Horne AP, Holme KR, Preuss JM, Page CP: Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol 1999; 46: 151-208 Cerca con Google

72. Cancian M, Bendo R, Caltarossa E, Peserico A, Fagiolo U: Sulodexide in the treatment of chronic idiopathic urticaria. It J Allergy Clin Immunol 2000; 10: S184 Cerca con Google

73. Konstantinou GN, Asero R, Maurer M, Sabroe RA, Schmid-Grendelmeier P, Grattan CE: EAACI/GALEN task force consensus report: the autologous serum skin test in urticaria. Allergy 2009; 64(9):1256-68 Cerca con Google

74. Soundararajan S, Kikuchi Y, Joseph K, Kaplan AP: Functional assessment of pathogenic IgG subclasses in chronic autoimmune urticaria. J Allergy Clin Immunol 2005; 115: 815-21 Cerca con Google

75. Grattan CEH, Boon AP, Eady RAJ, Winkelmann RK: The pathology of the autologous serum skin test response in chronic urticaria resembles IgE-mediated late-phase reactions. Int Arch Allergy Appl Immunol 1990; 93: 198-204 Cerca con Google

76. Barlow RJ, Ross EL, MacDonald DM, Kobza Black A, Greaves MW: Mast cells and T lymphocytes in chronic urticaria. Clin Exp Allergy 1995; 25: 317-22 Cerca con Google

77. Bossi F, Frossi B, Radillo O, Cugno M, Tedeschi A, Riboldi P, Asero R, Tedesco F, Pucillo C: Mast cell are critically involved in serum-mediated vascular leakage in chronic urticarial beyond high-affinity Ige receptor stimulation. Allergy 2011;66:1538-1545. Cerca con Google

78. Paganelli R, Fagiolo U, Cancian M, Scala E: Intestinal permeability in patients with chronic urticaria angioedema with and without arthralgia. Annals Allergy 1991; 66:181-4 Cerca con Google

79. Buhner S, Reese I, Kuehl F, Lochs H, Zuberbier T: Pseudoallergic reactions in chronic urticaria are associated with altered gastroduodenal permeability. Allergy 2004; 59: 1119-23 Cerca con Google

80. Pfrommer C, Bastl R, Vieths S, Ehlers I, Henz BM, Zuberbier T: Characterization of naturally occurring pseudoallergens causing chronic urticaria. J Allergy Clin Immunol 1996; 97: 367 Cerca con Google

81. Zuberbier T, Chantraine-Hess S, Hartmann K, Czarnetzki BM: Pseudoallergen free diet in the treatment of chronic urticaria - prospective study. Acta Derm Venereol 1995; 75: 484-7 Cerca con Google

82. Zuberbier T: Role of allergens and pseudoallergens in urticaria. J Invest Dermatol symp Proc 2001; 6: 132-4 Cerca con Google

83. Chong SU, Worm M, Zuberbier T: Role of adverse reactions to food in urticaria and exercise-induced anaphylaxis. Int Arch Allergy Immunol 2002; 129: 19-26 Cerca con Google

84. Asero R, Tedeschi A, Lorini M: Autoreactivity is highly prevalent in patients with multiple intolerance to NSAIDs. Ann Allergy Asthma Immunol 2002; 88: 468-72 Cerca con Google

85. Cancian M, Bendo R, Ossi E, Realdi G: Skin reactivity to autologous serum and safety of COX-2 inhibitors in NSAID-intolerant patients with urticaria and/or angioedema. Abstract Book World Allergy Congress, Bangkok 2007; n. 58 Cerca con Google

86. Fagiolo U, Kricek F, Ruf C, Peserico A, Amadori A, Cancian M: Effects of complement inactivation and IgG depletion on skin reactivity to autologous serum in chronic idiopathic urticaria. J Allergy Clin Immunol 2000; 106: 567-72 Cerca con Google

87. Horn MP, Gerster T, Ochensberger B, Derer T, Kricek F, Jouvin MH, Kinet JP, Tschernig T, Vogel M, Stadler BM, Miescher SM: Human anti-FcepsilonRIalpha autoantibodies isolated from healthy donors cross-react with tetanus toxoid. Eur J Immunol 1999; 29: 1139-48 Cerca con Google

88. Pachlopnik JM, Horn MP, Fux M, Dahinden M, Mandallaz M, Schneeberger D, Baldi L,Vogel M, Stadler BM, Miescher SM: Natural anti-FcRIautoandibodies may interfere with diagnostic tests for autoimmune urticaria. J Autoimmunity 2004; 22: 43-51 Cerca con Google

89. Auyeung P, Mittag D, Hodgkin PD, Harrison LC. Autoreactive T cells in chronic spontaneous urticaria target the IgE Fc receptor Iα subunit. J Allergy Clin Immunol. 2016 138(3):761-768 Cerca con Google

90. Cancian M: Il processo infiammatorio. In: Trattato di Medicina Interna. Crepaldi G and Baritussio A eds, Piccin Editore Publ, Padova, 2003, pp. 4274-4311 Cerca con Google

91. Asero R, Tedeschi A, Riboldi P, Cugno M: Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum. J Allergy Clin Immunol 2006; 117: 1113-7 Cerca con Google

92. Asero R, Tedeschi A, Riboldi P, Griffini S, Bonanni E, Cugno M: Severe chronic urticaria is associated with elevated plasma levels of D-dimer. Allergy 2008; 63: 176-80 Cerca con Google

93. Asero R, Tedeschi A, Coppola R, Griffini S, Paparella P, Riboldi P, Marzano AV, Fanoni D, Cugno M: Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria. J Allergy Clin Immunol 2007; 119: 705-10 Cerca con Google

94. Asero R, Cugno M, Tedeschi A: Activation of blood coagulation in plasma from chronic urticaria patients with negative autologous plasma skin test. JEADV 2011, 25, 201-205. Cerca con Google

95. Altrichter S, Peter HJ, Pisarevskaja D, Metz M, Martus P, Maurer M. IgE mediated autoallergy against thyroid peroxidase--a novel pathomechanism of chronic spontaneous urticaria? PLoS One. 2011 12;6(4): e14794 Cerca con Google

96. Kaplan AP, Giménez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. 2017 Apr;72(4):519-533. Cerca con Google

97 Saini S, Rosen KE, Hsieh HJ, Wong DA, Conner E, Kaplan A, Spector S, Maurer M.: A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011 Sep;128(3):567-73 Cerca con Google

98. Maurer M, Rosén K, Hsieh HJ, Saini S, Grattan C, Gimenéz-Arnau A, Agarwal S, Doyle R, Canvin J, Kaplan A, Casale T.: Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013 Mar 7;368(10):924-35. Cerca con Google

99. Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E, Veith J, Kamath N, Staubach P, Jakob T, Stirling RG, Kuna P, Berger W, Maurer M, Rosén K.: Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013 Jul;132(1):101-9. Cerca con Google

100. Zhao ZT, Ji CM, Yu WJ, Meng L, Hawro T, Wei JF, Maurer M. Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016 Jun;137(6):1742-1750 Cerca con Google

101 Shields RL, Whether WR, Zioncheck K, O'Connell L, Fendly B, Presta LG, Thomas D, Saban R, Jardieu P. Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):308-12 Cerca con Google

102. Holgate ST, Djukanović R, Casale T, Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy. 2005 Apr;35(4):408-16 Cerca con Google

103.Kolkhir P, André F, Church MK, Maurer M, Metz M.: Potential blood biomarkers in chronic spontaneous urticaria. Clin Exp Allergy. 2017 Jan;47(1):19-36 Cerca con Google

104. MacGlashan DW Jr, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, Sterbinsky SA, Hamilton RG, Lichtenstein LM. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997 Feb 1;158(3):1438-45. Cerca con Google

105. Metz M, Staubach P, Bauer A, Brehler R, Gericke J, Kangas M, Ashton-Chess J, Jarvis P, Georgiou P, Canvin J, Hillenbrand R, Erpenbeck VJ, Maurer M. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin. Theranostics. 2017 Mar 6;7(5):1266-1276 Cerca con Google

106. Deza G, Bertolín-Colilla M, Pujol RM, Curto-Barredo L, Soto D, García M, Hernández P, Gimeno R, Giménez-Arnau AM. Basophil FcεRI Expression in Chronic Spontaneous Urticaria: A Potential Immunological Predictor of Response to Omalizumab Therapy. Acta Derm Venereol. 2017 Jun 9;97(6):698-704 Cerca con Google

107. Gericke J, Metz M, Ohanyan T, Weller K, Altrichter S, Skov PS, Falkencrone S, Brand J, Kromminga A, Hawro T, Church MK, Maurer M.: Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. J Allergy Clin Immunol. 2017 Mar;139(3):1059-1061 Cerca con Google

108. Palacios T, Stillman L, Borish L, Lawrence M. Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria. J Allergy Clin Immunol Pract. 2016 May-Jun;4(3):529-30 Cerca con Google

109. MacGlashan DW Jr, Savage JH, Wood RA, Saini SS. Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factors. J Allergy Clin Immunol. 2012 Nov;130(5):1130-1135 Cerca con Google

110. Cardamone C, Parente R, Feo GD, Triggiani M. Mast cells as effector cells of innate immunity and regulators of adaptive immunity. Immunol Lett. 2016 Oct;178:10-4. Cerca con Google

111. Borriello F, Granata F, Varricchi G, Genovese A, Triggiani M, Marone G. Immunopharmacological modulation of mast cells. Curr Opin Pharmacol. 2014 Aug;17:45-57. Cerca con Google

112. Dudeck A, Suender CA, Kostka SL, von Stebut E, Maurer M: Mast cells promote Th1 and TH17 response by modulating dendritic cell maturation and function. European Journal of Immunology 2011, 41(7):1883-1893 Cerca con Google

113. C.B. Schmidt-Weber, M. Akdis, C.A. Akdis. TH17 cells in the big picture of immunology. J Allergy Clin Immunol 2007;120:247-54 Cerca con Google

114. Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005; 6:1133-41 Cerca con Google

115. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005; 6:1123-32 Cerca con Google

116. Waite JC, Skokos D.TH17 response and inflammatory autoimmune diseases. Int J Inflam. 2012;2012:819467 Cerca con Google

117. Fasching P, Stradner M, Graninger W, Dejaco C, Fessler J. Therapeutic Potential of Targeting the TH17/Treg Axis in Autoimmune Disorders. Molecules. 2017 Jan 14;22(1) Cerca con Google

118. Aujla SJ, Chan YR, Zheng M, et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med. 2008; 14:275-81 Cerca con Google

119. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008; 28:454-67 Cerca con Google

120 Hoe E, Anderson J, Nathanielsz J, Toh ZQ, Marimla R, Balloch A, Licciardi PV. The contrasting roles of TH17 immunity in human health and disease. Microbiol Immunol. 2017 Feb;61(2):49-56 Cerca con Google

121. Chung DR, Kasper DL, Panzo RJ, et al. CD4+ T cells mediate abscess formation in intra-abdominal sepsis by an IL-17-dependent mechanism. J Immunol 2003; 170:1958-63 Cerca con Google

122. Infante-Duarte C, Horton HF, Byrne MC, et al. Microbial lipopeptides induce the production of IL-17 in Th cells. J Immunol 2000; 165:6107-15 Cerca con Google

123. Khader SA, Bell GK, Pearl JE, et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007; 8:369-77 Cerca con Google

124. Huang W, Na L, Fidel PL, et al. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis 2004; 190:624-31 Cerca con Google

125. Mogensen TH. Primary Immunodeficiencies with Elevated IgE. Int Rev Immunol. 2016;35(1):39-56. Cerca con Google

126. Murdaca G, Colombo BM, Puppo F: The role of TH17 lymphocytes in the autoimmune and chronic inflammatory diseases. Intern Emerg Med 2011; 6:487–495 Cerca con Google

127. Peck A, Mellins ED: Breaking old paradigms: TH17 cells in autoimmune arthritis. Clin Immunol 2009; 132(3):295–304 Cerca con Google

128. Nalbandian A, Crispın JC, Tsokos GC: Interleukin-17 and systemic lupus Cerca con Google

erythematosus: current concepts. Clin ExpImmunol (2009) 157(2):209–215] + [Zhang Z, Kyttaris VC, Tsokos GC: The role of IL-23/IL-17axis in lupus nephritis. J Immunol 2009; 183(5):3160316–3160319 Cerca con Google

129. Bennett JL, Stüve O: Update on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implications. Clin Neuropharmacol 2009; 32(3):121–132 Cerca con Google

130. Brand S: Crohn’s disease: Th1, TH17 or both? The change of a paradigm: new immunological and genetic insights implicate TH17 cells in the pathogenesis of Crohn’s disease. Gut 2009; 58(8): 1152–1167 Cerca con Google

131. Han L, Yang J, Wang X, Li D, Lv L, Li B. TH17 cells in autoimmune diseases. Front Med. 2015 Mar;9(1):10-9. Cerca con Google

132. Ciprandi G, Filaci G, Battaglia F, Fenoglio D: Peripheral Th-17 cells in allergic rhinitis: Cerca con Google

new evidence. Int Immunopharmacol 2010;10(2):226–229 Cerca con Google

133. Lajoie S, Lewkowich IP, Suzuki Y, Clark JR, Sproles AA, Dienger K et al: Complement-mediated regulation of the IL-17A axis is a central genetic determinant of the severity of experimental allergic asthma. Nat Immunol 2010;11(10):928–935 Cerca con Google

134 Jonuleit H, Schmitt E. The regulatory T cell family: distinct subsets and their interrelations. J Immunol. 2003 Dec 15;171(12):6323-7 Cerca con Google

135 Sasaki N, Yamashita T, Takeda M, Hirata K. Regulatory T cells in atherogenesis. J Atheroscler Thromb. 2012;19(6):503-15 Cerca con Google

136. Gagliani N, Amezcua Vesely MC, Iseppon A, Brockmann L, Xu H, Palm NW, de Zoete MR, Licona-Limón P, Paiva RS, Ching T, Weaver C, Zi X, Pan X, Fan R, Garmire LX, Cotton MJ, Drier Y, Bernstein B, Geginat J, Stockinger B, Esplugues E, Huber S, Flavell RA. TH17 cells transdifferentiate into regulatory T cells during resolution of inflammation. Nature. 2015 Jul 9;523(7559):221-5 Cerca con Google

137. Horwitz DA, Zheng SG, Gray JD. Natural and TGF-beta-induced Foxp3(+)CD4(+) CD25(+) regulatory T cells are not mirror images of each other. Trends Immunol. 2008 Sep;29(9):429-35. Cerca con Google

138. Buckner JH: Mechanism of impaired regulation by CD4+CD25+FOXP3+ regulatory T cells in human autoimmune diseases. Nat Rev Immunol 2010; 10(12):849–859 Cerca con Google

139. Diller ML, Kudchadkar RR, Delman KA, Lawson DH, Ford ML. Balancing Inflammation: The Link between TH17 and Regulatory T Cells. Mediators Inflamm. 2016;2016:6309219. Cerca con Google

140. Noack M, Miossec P. TH17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev. 2014 Jun;13(6):668-77. Cerca con Google

141. Yadav M, Stephan S, Bluestone JA. Peripherally induced tregs - role in immune homeostasis and autoimmunity. Front Immunol. 2013 Aug 7;4:232. Cerca con Google

142. Lee KY, Mukasa R, Hatton RD, Weaver CT: Developmental plasticity of TH17 and Treg cells. Current Opinion in Immunology 2009; 21:274-280 Cerca con Google

143. W.C. Chen et al: Defective function of circulating CD4+CD25+ and CD4+CD25- T cells in patients with chronic ordinary urticaria. Journal of dermatological science 2008;51, 121-130 Cerca con Google

144. R.S. Sun et al. Detection of CD+CD25+FOXP3+ regulatory T cells in peripheral blood of patients with chronic autoimmune urticaria. Australasian Journal of Dermatology 2011;52, e15-e18 Cerca con Google

145. Lopes A, Machado D, Pedreiro S, Henriques A, Silva I, Tavares B, Inácio MJ, Chieira C, Martinho A, Pais ML, Pereira C, Paiva A. Different frequencies of Tc17/Tc1 and TH17/Th1 cells in chronic spontaneous urticaria. Int Arch Allergy Immunol. 2013;161(2):155-62. Cerca con Google

146. Moy AP, Murali M, Nazarian RM. Identification of a Th2- and TH17-skewed immune phenotype in chronic urticaria with Th22 reduction dependent on autoimmunity and thyroid disease markers. J Cutan Pathol. 2016 Apr;43(4):372-8 Cerca con Google

147. Chandrashekar L, Rajappa M, Munisamy M, Ananthanarayanan PH, Thappa DM, Arumugam B. 25-Hydroxy vitamin D levels in chronic urticaria and its correlation with disease severity from a tertiary care centre in South India. Clin Chem Lab Med. 2014 Jun;52(6):e115-8 Cerca con Google

148. Atwa MA, Emara AS, Youssef N, Bayoumy NM. Serum concentration of IL-17, IL-23 and TNF-α among patients with chronic spontaneous urticaria: association with disease activity and autologous serum skin test. J Eur Acad Dermatol Venereol. 2014 Apr;28(4):469-74. Cerca con Google

149. Grzanka A, Damasiewicz-Bodzek A, Kasperska-Zajac A. The relationship between circulating concentrations of interleukin 17 and C reactive protein in chronic spontaneous urticaria. Allergy Asthma Clin Immunol. 2017 May 10;13:25 Cerca con Google

150. L.C. dos Santos et al. Increased circulating pro-inflammatory cytokines and imbalanced Cerca con Google

regulatory T-cell cytokines production in chronic idiopathic urticaria. International immunopharmacology 2008; 1433-1440 Cerca con Google

151. Valencia X, Lipsky PE. CD4+CD25+FoxP3+ regulatory T cells in autoimmune diseases. Nat Clin Pract Rheumatol. 2007 Nov;3(11):619-26 Cerca con Google

152. Song X, Gao H, Qian Y. Th17 differentiation and their pro-inflammation function. Cerca con Google

Adv Exp Med Biol. 2014;841:99-151. Cerca con Google

153. Du R, Zhao H, Yan F, Li H. IL-17+Foxp3+ T cells: an intermediate differentiation stage between Th17 cells and regulatory T cells. J Leukoc Biol. 2014 Jul;96(1):39-48. Cerca con Google

154. Damsker JM, Hansen AM, Caspi RR. Th1 and Th17 cells: adversaries and collaborators.Ann N Y Acad Sci. 2010 Jan;1183:211-21. Cerca con Google

155. Maggi L, Santarlasci V, Capone M, Rossi MC, Querci V, Mazzoni A, Cimaz R, De Palma R, Liotta F, Maggi E, Romagnani S, Cosmi L, Annunziato F. Distinctive features of classic and nonclassic (Th17 derived) human Th1 cells. Eur J Immunol. 2012 Dec;42(12):3180-8 Cerca con Google

156. Harbour SN, Maynard CL, Zindl CL, Schoeb TR, Weaver CT. Th17 cells give rise to Th1 cells that are required for the pathogenesis of colitis. Proc Natl Acad Sci U S A. 2015 Jun 2;112(22):7061-6 Cerca con Google

157. Cosmi L, Maggi L, Santarlasci V, Capone M, Cardilicchia E, Frosali F, Querci V, Angeli R, Matucci A, Fambrini M, Liotta F, Parronchi P, Maggi E, Romagnani S, Annunziato F. Identification of a novel subset of human circulating memory CD4(+) T cells that produce both IL-17A and IL-4. J Allergy Clin Immunol. 2010 Jan;125(1):222-30 Cerca con Google

158. McGeachy MJ, Chen Y, Tato CM, Laurence A, Joyce-Shaikh B, Blumenschein WM, McClanahan TK, O'Shea JJ, Cua DJ. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol. 2009 Mar;10(3):314-24. Cerca con Google

Download statistics

Solo per lo Staff dell Archivio: Modifica questo record